News from the 12th Annual Congress ECAS: Results from the REVISIT-US retrospective analysis

Abstract:

Registration studies for novel oral anticoagulants have demonstrated favourable benefit risk profile versus vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation. In real world settings, these drugs are used in much broader population, and not necessarily in the same way as in their registration studies. Therefore additional evidence from real world clinical research is needed to confirm the benefit-risk balance. To date rivaroxaban performance has been evaluated in a number of real world clinical practice studies, both prospectively and retrospectively. One after another, these studies continue to confirm that rivaroxaban performs as expected, with a positive balance of benefits and risk. Results from the REVISIT-US (Real-world EVIdence on Stroke prevention In patients with aTrial Fibrillation in the United States) retrospective analysis are another in a series of such evidence.

Key words:
apixaban; atrial fibrillation; clinical efficacy; rivaroxaban; safety